Who is sponsoring NCT00668642?

NCT00668642 is sponsored by Endeavor Health.

What condition does NCT00668642 study?

NCT00668642 studies Prostate Cancer.

What drugs are being tested in NCT00668642?

Interventions: Dutasteride, Placebo.

What is the status of NCT00668642?

NCT00668642 is currently COMPLETED.

Last reviewed 2023-07-26 · How we verify

Effect of Dutasteride on Androgen-Response Gene Expression During the Tumor Regrowth Phase of Intermittent Androgen Ablation Therapy in Patients With Advanced Prostate Cancer

NCT00668642 Phase 2 COMPLETED Results posted

The purpose of this study is to determine if the drug dutasteride increases expression of genes that slow the growth of prostate cancer during treatment with intermittent androgen ablation therapy (hormone therapy).

Details

Lead sponsor	Endeavor Health
Phase	Phase 2
Status	COMPLETED
Enrolment	20
Start date	2007-03
Completion	2013-05

Conditions

Prostate Cancer

Interventions

Dutasteride
Placebo

Primary outcomes

Relative Expression of U19 Gene in Tumor From Prostate Gland During First Off-cycle. — At the end of off-cycle 1 defined by when the testosterone level reaches normal (approximately 6 months)
Calculation of the level of gene expression of the U19 tumor suppressor gene compared between the 2 arms at the end of "off-treatment" cycle 1.

Countries

United States